Key result
Growth hormone treatment links to lower CRP and P-selectin levels in deficient adolescents.
Why the study?
The circulating concentrations of markers of vascular endothelial cell and platelet activation and their relationship to inflammatory markers have not been previously evaluated in growth hormone-deficient adolescents.
Does growth hormone treatment improve circulating levels of CRP and markers of vascular endothelial cell activation in growth hormone-deficient adolescents?
Cross-Sectional (n=60)
Does growth hormone treatment improve circulating levels of CRP and markers of vascular endothelial cell activation in growth hormone-deficient adolescents?
Low-grade inflammation and early activation of vascular endothelial cells in growth hormone-deficient adolescents appear to be mitigated by growth hormone treatment.
Answers are grounded in this paper and cite their sources.
May support growth hormone mitigating inflammation in deficient adolescents; hypothesis-generating for cardiovascular outcomes, needing prospective trials.
BACKGROUND/AIMS: Significant endothelial dysfunction as determined by lower flow-mediated vasodilation of the brachial artery was recently reported by us in growth hormone-deficient (GHD) adolescents. The circulating concentrations of markers of vascular endothelial cell and platelet activation and their relationship to inflammatory markers have not been previously evaluated in this group of patients. OBJECTIVE: To assess the relationship between circulating levels of high-sensitivity C-reactive protein (CRP) and soluble markers of vascular endothelial cell activation in GHD adolescents. DESIGN/METHODS: Twenty-eight GHD children on GH treatment with a chronological age of 15.7 +/- 2.6 years and 16 untreated GHD adolescents with a chronological age of 16.6 +/- 3.3 years were studied. Concentrations of CRP, as an inflammatory marker, were measured in all patients and the association between CRP and the fasting soluble markers of vascular endothelial cell activation intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin and P-selectin levels was evaluated. Sixteen healthy adolescents with a mean chronological age of 15.1 +/- 2.2 years served as controls. RESULTS: CRP and P-selectin levels were significantly higher in untreated GHD adolescents than in treated GHD subjects or in healthy controls (p < 0.02), while VCAM-1 concentrations were increased in both untreated and treated GHD adolescents when compared to controls (p < 0.007). E-selectin and ICAM-1 levels were similar in all three groups. CRP was found to be associated with BMI (r: 0.62; p < 0.001), P-selectin (r: 0.43; p < 0.01), E-selectin (r: 0.27; p < 0.03), ICAM-1 (r: 0.23; p < 0.05) and VCAM-1 (r: 0.40; p < 0.001) concentrations in untreated GHD adolescents and with P-selectin (r: 0.88; p < 0.001) and E-selectin (r: 0.29; p < 0.01) in treated GHD subjects. A weak inverse association was observed in a subgroup of patients between brachial artery endothelium-dependent dilation and P-selectin (r: -0.56; p < 0.07). CONCLUSIONS: Low-grade inflammation as manifested by increased circulating levels of CRP seems to be associated with the early activation of vascular endothelial cells in GHD adolescents.
No takes yet. Share an insight, caveat, or question.
Lanes et al. (2008) conducted a cross-sectional in Growth hormone deficiency (n=60). Untreated growth hormone deficiency vs. GH treatment and healthy controls was evaluated on Circulating levels of CRP and P-selectin (p=<0.02). Untreated growth hormone-deficient adolescents had higher CRP and P-selectin levels compared to treated patients or healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: